Date published: 2025-12-21

1-800-457-3801

SCBT Portrait Logo
Seach Input

PNPLA7 Inhibitors

PNPLA7, or Patatin-Like Phospholipase Domain Containing 7, is a member of the patatin-like phospholipase domain-containing protein family. These proteins are characterized by their patatin domain, which is typically involved in lipid metabolism. PNPLA7 is a multifunctional enzyme endowed with lipolytic activity. It plays a significant role in various cellular processes, particularly in the regulation of adipocyte differentiation. Adipocytes, specialized in storing energy as fat, undergo a transition from precursor cells to mature fat cells, a process termed differentiation. PNPLA7 has been implicated in this differentiation process. In addition to adipocyte differentiation, this protein is also known to respond to metabolic stimuli, emphasizing its involvement in metabolic regulation. It is expressed in a variety of tissues, including those that are target tissues for insulin, such as skeletal muscle, heart, and adipose tissues. Within these tissues, PNPLA7 is believed to play a role in regulating the metabolic responses to feeding and fasting.

The class of PNPLA7 inhibitors encompasses chemicals that act to attenuate or halt the function of the PNPLA7 protein. The action of these inhibitors may be direct, binding to specific sites on the protein and thereby affecting its activity, or indirect, influencing upstream or downstream pathways that, in turn, modulate PNPLA7's functionality. Given the protein's role in adipocyte differentiation and metabolic responses, the inhibitors, in general, are envisioned to alter these processes by modulating the activity of PNPLA7. The mode of action and potency of these inhibitors can vary, ranging from those that interfere with the enzyme's substrate binding to those that impact the protein's conformation or stability. Additionally, while some inhibitors may target the protein specifically, others might display broader specificity, affecting related enzymes or pathways. The design and study of PNPLA7 inhibitors is an ongoing area of research, driven by the aim to gain a better understanding of the intricate mechanisms underpinning lipid metabolism and cellular differentiation.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rosiglitazone

122320-73-4sc-202795
sc-202795A
sc-202795C
sc-202795D
sc-202795B
25 mg
100 mg
500 mg
1 g
5 g
$118.00
$320.00
$622.00
$928.00
$1234.00
38
(1)

A thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ plays a pivotal role in adipocyte differentiation. By modulating this pathway, Rosiglitazone could influence PNPLA7 indirectly.

AICAR

2627-69-2sc-200659
sc-200659A
sc-200659B
50 mg
250 mg
1 g
$60.00
$270.00
$350.00
48
(2)

An analog of AMP, known to activate AMPK, which in turn affects lipid metabolism pathways and could indirectly influence PNPLA7.

GW 9662

22978-25-2sc-202641
5 mg
$68.00
30
(2)

A PPARγ antagonist. By inhibiting PPARγ, it could indirectly impact adipocyte differentiation and thus PNPLA7 activity.

WY 14643

50892-23-4sc-203314
50 mg
$133.00
7
(1)

An agonist for PPARα, which plays a role in lipid metabolism. By modulating lipid metabolism, it might have indirect effects on PNPLA7.

T0070907

313516-66-4sc-203287
5 mg
$138.00
1
(1)

A potent and selective PPARγ antagonist. It can affect adipocyte differentiation, potentially influencing PNPLA7.

Troglitazone

97322-87-7sc-200904
sc-200904B
sc-200904A
5 mg
10 mg
25 mg
$108.00
$200.00
$426.00
9
(1)

Another thiazolidinedione that activates PPARγ. Like Rosiglitazone, it could indirectly influence PNPLA7 by impacting adipocyte differentiation.

Retinoic Acid, all trans

302-79-4sc-200898
sc-200898A
sc-200898B
sc-200898C
500 mg
5 g
10 g
100 g
$65.00
$319.00
$575.00
$998.00
28
(1)

It plays a role in cell differentiation and growth. It might indirectly modulate adipocyte differentiation, potentially affecting PNPLA7.

BML-275

866405-64-3sc-200689
sc-200689A
5 mg
25 mg
$94.00
$348.00
69
(1)

An inhibitor of AMPK. By targeting the AMPK pathway, it might indirectly modulate PNPLA7's activity.